Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-09-22 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding the receipt of an Establishment Inspection Report (EIR) from the US FDA for the company's Aurangabad facility. It references a prior intimation and is made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosures of material events. The document does not contain any financial data, detailed audit results, or full reports but is an announcement of a regulatory inspection outcome. The length is only 1681 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-22 English
General updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges regarding an update on the company's manufacturing facility status following a US FDA inspection. It references a prior intimation and provides regulatory disclosure under SEBI Listing Obligations. The document is only 1906 characters long and does not contain any financial data, detailed report, or analysis. It is an announcement of a regulatory update rather than a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-22 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 60% confidence The document is very short (245 characters) and contains a table listing an investor event with date, venue, and type labeled as 'Call'. There is no substantive financial data, no detailed report content, and no indication of a report being attached or published. The content resembles an announcement or schedule of an investor call event rather than a transcript or report. Given the event type is 'Call', this document is best classified as a Call Transcript (CT) if it contained the full transcript, but since it only lists the event without transcript content, it is more likely an announcement or schedule. However, since no other category fits better and the document is minimal, the fallback is Regulatory Filings (RNS). But considering the event type is 'Call' and the document is about an investor event, the best fit is Investor Presentation (IP) or Call Transcript (CT). Since it is not a presentation but a call event listing, the closest is Call Transcript (CT) category, assuming this is a call event notice or summary. Confidence is moderate due to minimal content.
2022-09-07 English
Press Release
Regulatory Filings
2022-08-30 English
Newspaper Advertisements
Regulatory Filings
2022-08-29 English
General updates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (BSE and NSE) regarding an update on the company's Goa facility following a US FDA inspection. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements, Regulation 30, which pertains to continuous disclosures of material events. The content discusses the FDA's classification of the inspection as 'Official Action Indicated' and the company's commitment to resolving the issues. The document is short (2361 characters), does not contain financial data, financial statements, or detailed report content, and is clearly an announcement of a regulatory or compliance update. It is not an annual report, earnings release, or any detailed financial or management report. It fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure about a material event affecting the company, without being a full report or financial document.
2022-08-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.